Share

Profile & Fundamentals

Innovent Biologics Profile & Fundamentals

Name: Innovent Biologics financial chart data preview
Creator: iPulse AI
License: https://ipulseai.com/terms

Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.

Interactive annual & quarterly chartsAI financial reviewsReported source tables

Explore this pageJump to a Profile & Fundamentals section

Explore this research

Profile & Fundamentals contents

Jump directly to any section

Company and Market Context

Company Profile & Ownership

Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverembatinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), DUPERT (fulzerasib), DOVBLERON (taletrectinib adipate), Jaypirca (pirtobrutinib), limertinib, SYCUME (teprotumumab N01 injection), mazdutide, PECONDLE (picankibart injection), and TABOSUN(Ipilimumab N01 injection). In addition, it sells and distributes pharmaceutical products; and offers consultation and research and development services. The company was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.

Company profile record

Innovent Biologics Inc

Common Stock · Health Care · Biotechnology

Official website

Company

Company / asset: Innovent Biologics Inc
Security type: Common Stock
Sector: Health Care
Industry: Biotechnology
HQ: 🇨🇳 China
Head office: 168 Dongping Street, Suzhou, China, 215123

Leadership & scale

Chief executive: Dr. De-Chao Yu Ph.D.
CEO year born: 1964
Full-time employees: 8.8K
Fiscal year end: December

Fundamentals snapshot

Updated 2026-09-12

Market Cap: HKD 179.6B
P/E: 68.6x
Revenue (Q2 26): CNY 8.5B
Profit (Q2 26): CNY 1.2B
Dividend Yield: --
Revenue (FY 25): CNY 13.0B
Shares in public float: 1.6B
Insider ownership: 6.24%

Reporting & identifiers

Symbol: 1801.HKEX
Listing: 🇭🇰 Hong Kong | Dividend Tax: 0%
Ticker Currency: HKD
Income Statement Currency: CNY
Balance Sheet Currency: CNY
Cash Flow Currency: CNY
EPS Currency: CNY
Contract Type: SPOT
ISIN: KYG4818G1010
Asset ID: equity_e575933a-1490-5bf1-9c5e-635db20b4cac

Ownership

Shares Outstanding

Shares outstanding

Annual reported shares outstanding. Values in shares.

Earnings, Profitability & Valuation

Earnings & Revenue

AI Review

Innovent has crossed an important financial threshold by turning years of clinical development losses into steady commercial profitability. Revenue for the first half of 2026 reached CNY 8.50 billion, supported by robust oncology prescriptions and the initial commercial rollout of mazdutide. Net profit expanded to CNY 1.24 billion, demonstrating that expanding product sales are successfully covering routine business expenses. However, reported headlines require careful interpretation. A significant portion of 2025's massive free cash flow stemmed from large upfront collaboration payments rather than pure product sales. The true test of ongoing financial health lies in recurring product revenues, which must continue compounding to support advanced clinical trials as partnership windfalls normalize.

Revenue, Net Income, and Free Cash Flow

Revenue
Free cash flow
Net income

Annual reported financial results, converted using the statement's recorded USD conversion. Missing values are omitted. Values in USD.

Valuation

Historical P/E Ratio

The published data is insufficient to draw this chart.

Profitability & Margins

AI Review

Gross profit margins have stabilized near 76.7%, reflecting high-margin proprietary biologics and efficient large-scale factory production. Operating margins have turned decisively positive, recovering from deep historical deficits to exceed 12% in the first half of 2026. This improvement demonstrates classic operating leverage, where fixed sales and administrative costs dilute as overall sales volumes expand. Maintaining these margins will involve balancing opposing forces. Routine government reimbursement price cuts and generic competition will exert downward pressure on older oncology lines. However, rising sales of premium metabolic therapies and high-margin international licensing royalties are expected to defend consolidated net margins near double-digit levels.

Profitability Margins

Gross margin
Operating margin
Net margin
Free cash flow margin

Annual gross, operating, net income and free cash flow divided by revenue for matching reporting dates. Values in percent.

Complete Research Workspace

Unlock the complete Profile & Fundamentals

Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.

Sign in to check access View Base plan

Paywalled preview begins: Reported Data Tables — chart preview

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Reported Data Tables — chart preview

The following tables contain the same values as the financial charts above. Monetary values are USD; margins are percentages. Missing inputs are not estimated. Use is subject to the iPulse AI Terms of Service and applicable source rights.

Source: eodhd. Statement snapshots with chart transformations and ratios calculated by iPulse AI. Snapshot retrieved 2026-09-15.

Annual earnings and profitability
Period end	Revenue	Free cash flow	Net income	Gross margin	Operating margin	Net margin	Free cash flow margin
2016-12-31	4,145,439.23	-54,378,967.74	-65,058,580.65	100	-1,436.6	-1,569.4	-1,311.78
2017-12-31	2,373,623.56	-74,678,745.2	-71,999,743.92	485.54	-4,046.48	-3,033.33	-3,146.19
2018-12-31	1,210,344.83	-169,700,894	-737,099,872.29	113.84	-18,841.75	-60,899.99	-14,020.87
2019-12-31	134,470,474.97	-260,634,916.56	-220,789,473.68	88.08	-158.76	-164.19	-193.82
2020-12-31	495,976,645.16	-139,285,935.48	-128,828,516.13	89.91	-14.5	-25.97	-28.08
2021-12-31	671,341,037.74	-608,861,477.99	-493,404,559.75	86.58	-69.99	-73.5	-90.69
2022-12-31	660,344,927.54	-478,338,260.87	-315,836,231.88	79.57	-68.54	-47.83	-72.44
2023-12-31	794,631,242	-174,035,211.27	-131,614,980.79	70.89	-27.06	-16.56	-21.9
2024-12-31	1,212,598,198.2	-53,846,589.45	-12,179,021.88	83.97	-8.02	-1	-4.44
2025-12-31	1,865,740,057.22	1,333,009,728.18	116,389,842.63	76.66	5.63	6.24	71.45

Published valuation snapshots
Period end	P/E (times earnings)	Earnings basis
2025-12-31	172.38	Trailing four quarters

Shares outstanding — chart values
Reporting date	Shares outstanding
2017-01-01	101,515,900
2018-01-01	523,544,700
2019-01-01	1,262,562,200
2020-01-01	1,402,776,000
2021-01-01	1,460,986,200
2022-01-01	1,515,216,700
2023-01-01	1,583,953,400
2024-01-01	1,632,087,200
2025-01-01	1,787,569,200
2026-01-01	1,800,946,000

End of the paywalled preview

The excerpt from Reported Data Tables — chart preview to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Earnings, Profitability & Valuation
- Complete profitability ratios
- EPS history and estimate comparisons
- Execution vs expectations
- Annual and quarterly financial views
Capital Expenditure & R&D
- Capital allocation AI review
- Annual capital expenditure
- Investment intensity trends
- Capex and R&D intensity indicators
Balance Sheet
- Balance sheet AI review
- Assets, debt and equity
- Capital structure
- Liquidity and leverage
- Retained earnings
Dividends & Actions
- Cash dividends paid
- Dividend indicators
- Buybacks and issuance
- Combined shareholder returns
- Available corporate actions

Explore complete public research examples

These public assets show the complete asset profiles, fundamental datasets and analysis. Their findings concern those assets, not this report.